Copay maximizer market seen reaching $2.24B by 2030

By AI, Created 4:30 PM UTC, May 18, 2026, /AGP/ – The copay maximizer solutions market is projected to grow from $1.14 billion in 2025 to $2.24 billion by 2030, driven by specialty drug costs, high-deductible health plans and automation in pharmacy benefit management. North America led in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Copay maximizer solutions help health plans and employers lower patient out-of-pocket pressure on costly specialty drugs while keeping more manufacturer assistance from counting against deductibles and out-of-pocket limits. - The market is expanding as payers look for tools that reduce specialty drug spending and support medication adherence. - The Business Research Company projects the market will reach $2.24 billion by 2030.

What happened: - The Business Research Company released a 2026 market report on copay maximizer solutions. - The report says the market will grow from $1.14 billion in 2025 to $1.3 billion in 2026. - The report forecasts a 14.4% CAGR for 2025-2026 and a 14.6% CAGR from 2026-2030. - The report also says the market is set for faster expansion through 2030 as specialty drug costs rise and benefit-management tools become more automated. - The report includes a free sample and the full report.

The details: - Copay maximizer solutions are pharmacy benefit programs used by health plans and employers to manage expenses tied to specialty medications. - The programs maximize manufacturer copay assistance while limiting how much of that assistance counts toward a patient’s deductible or out-of-pocket cap. - Historic growth has been driven by rising specialty drug prices, broader use of pharmacy benefit programs, tighter payer cost controls, expansion in specialty pharmacy networks and improvements in claims processing. - Forecast growth drivers include AI-powered analytics, cloud-based platforms, patient assistance program software, real-time eligibility verification and outcome-based specialty drug management. - Other trends flagged by the report include benefit optimization software, patient assistance program management, automation in claims processing, enhanced eligibility verification and more specialty pharmacy services. - The report says specialty drugs include biologics, gene therapies and treatments for chronic, rare or severe diseases. - The report cites U.S. prescription drug spending of about $600 billion in 2023, with specialty medications accounting for $237 billion, or nearly 39.5% of total spending. - The report also cites data showing about 51% of private industry workers enrolled in medical plans were covered by high-deductible health plans in April 2024.

Between the lines: - Specialty drug spending is becoming harder to absorb for employers and payers, which helps explain why tools that optimize copay assistance are gaining traction. - High-deductible plans shift more cost to patients upfront, increasing demand for programs that soften the impact of expensive therapies. - The report’s emphasis on AI, cloud software and real-time verification suggests the market is moving from manual benefit administration toward more automated, data-driven workflows. - North America held the largest market share in 2025, while Asia-Pacific is expected to post the fastest growth through the forecast period.

What’s next: - The market is expected to keep scaling as payers expand use of benefit optimization and specialty pharmacy management tools. - Adoption should rise where specialty drug utilization, patient assistance programs and high-deductible coverage are all increasing. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.